[go: up one dir, main page]

IL164438A0 - Sustaubed release of guaifenesin combination drugs - Google Patents

Sustaubed release of guaifenesin combination drugs

Info

Publication number
IL164438A0
IL164438A0 IL16443803A IL16443803A IL164438A0 IL 164438 A0 IL164438 A0 IL 164438A0 IL 16443803 A IL16443803 A IL 16443803A IL 16443803 A IL16443803 A IL 16443803A IL 164438 A0 IL164438 A0 IL 164438A0
Authority
IL
Israel
Prior art keywords
sustaubed
release
combination drugs
guaifenesin
guaifenesin combination
Prior art date
Application number
IL16443803A
Original Assignee
Adams Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/121,706 external-priority patent/US6955821B2/en
Priority claimed from US10/406,557 external-priority patent/US7838032B2/en
Priority claimed from US10/406,574 external-priority patent/US7985420B2/en
Application filed by Adams Lab Inc filed Critical Adams Lab Inc
Publication of IL164438A0 publication Critical patent/IL164438A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16443803A 2002-04-15 2003-04-15 Sustaubed release of guaifenesin combination drugs IL164438A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/121,706 US6955821B2 (en) 2000-04-28 2002-04-15 Sustained release formulations of guaifenesin and additional drug ingredients
US10/406,557 US7838032B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin
US10/406,574 US7985420B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin combination drugs

Publications (1)

Publication Number Publication Date
IL164438A0 true IL164438A0 (en) 2005-12-18

Family

ID=29255202

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16443803A IL164438A0 (en) 2002-04-15 2003-04-15 Sustaubed release of guaifenesin combination drugs

Country Status (10)

Country Link
EP (1) EP1503739A4 (en)
JP (1) JP5466346B2 (en)
CN (1) CN1655766B (en)
AU (1) AU2003237807B2 (en)
CA (1) CA2481739C (en)
EA (1) EA007156B1 (en)
IL (1) IL164438A0 (en)
MX (1) MXPA04010225A (en)
WO (1) WO2003088952A1 (en)
ZA (1) ZA200409171B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040134A1 (en) 2002-07-25 2004-03-06 Pharmacia Corp PRAMIPEXOL ONCE-A-DAY DOSAGE FORM
JP2007517766A (en) * 2003-09-24 2007-07-05 コンビナトアールエックス インコーポレーティッド Treatment for administering a combination of drugs
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
NZ589267A (en) * 2004-08-13 2012-06-29 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
HUE025173T2 (en) 2005-12-13 2016-01-28 Incyte Corp Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
CN1994285B (en) * 2006-01-04 2011-03-16 上海医药工业研究院 Sustained release micro-pellet of guaifenesin and preparation process thereof
WO2008089260A2 (en) * 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
CN101658507B (en) * 2008-08-26 2011-12-07 北京科信必成医药科技发展有限公司 Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation
BRPI1007484B1 (en) 2009-02-04 2019-04-16 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FORMED ORAL ADMINISTRATION UNDERSTANDING A LAYER UNDERSTANDING A MODIFIED RELEASE PART AND A LAYER UNDERSTANDING AN IMMEDIATE RELEASE PART
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US9339478B2 (en) 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
ES2560611T3 (en) 2011-06-20 2016-02-22 Incyte Holdings Corporation Phenyl azetidinyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
CN102755304A (en) * 2012-08-03 2012-10-31 四川百利药业有限责任公司 Preparation method of guaifenesin and dextromethorphan hydrobromide capsules
SG10202111768XA (en) 2012-11-15 2021-11-29 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
CN114010611B (en) 2013-08-07 2023-11-28 因赛特控股公司 Sustained release dosage forms of JAK1 inhibitors
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
CN105982860B (en) * 2015-02-11 2020-04-14 北京科信必成医药科技发展有限公司 Guaifenesin Anhydrous Swallow Taste Masking Granules
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
ATE424810T1 (en) * 1998-12-11 2009-03-15 Nostrum Pharmaceuticals Inc A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
CA2383405A1 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
US6372525B1 (en) * 1999-12-20 2002-04-16 Taiwan Semiconductor Manufacturing Company Wafer-level antenna effect detection pattern for VLSI
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US20020022058A1 (en) * 2000-07-08 2002-02-21 Lovercheck Dale R. Unit dose of material in system and method

Also Published As

Publication number Publication date
JP5466346B2 (en) 2014-04-09
EA200401369A1 (en) 2005-06-30
ZA200409171B (en) 2005-07-27
AU2003237807B2 (en) 2008-10-23
AU2003237807A1 (en) 2003-11-03
CN1655766A (en) 2005-08-17
CA2481739C (en) 2012-10-02
CA2481739A1 (en) 2003-10-30
CN1655766B (en) 2012-05-30
EP1503739A4 (en) 2006-06-21
WO2003088952A1 (en) 2003-10-30
EA007156B1 (en) 2006-08-25
EP1503739A1 (en) 2005-02-09
MXPA04010225A (en) 2005-07-05
JP2005528402A (en) 2005-09-22

Similar Documents

Publication Publication Date Title
IL164438A0 (en) Sustaubed release of guaifenesin combination drugs
IL236190A0 (en) Sustained release of antiinfectives
PL373914A1 (en) Immediate release dosage forms containing solid drug dispersions
GB0225030D0 (en) Medicinal compounds
EG24479A (en) Modified release pharmaceutical formulation
EP1553925A4 (en) Modified release oral dosage form
AU2003260803A8 (en) Sustained release pharmaceutical composition
PL377495A1 (en) Solid drug for oral use
AU2003284634A1 (en) Sustained release drug carrier
PL376840A1 (en) Prolonged release pharmaceutical composition
EP1895991A4 (en) Modified release formulations of anti-irritability drugs
GB0202900D0 (en) Novel formulations of drugs
IL165069A0 (en) Immediate release pharmaceutical formulation
IL173738A0 (en) Modafinil modified release pharmaceutical compositions
IL176222A0 (en) Sustained release torsemide dosage forms
IL163887A0 (en) Controlled release dosage forms
EP1478353A4 (en) Sustained release pharmaceutical composition
EP1484061A4 (en) Drugs containing riboflavin-type compounds
EP1501844A4 (en) Disaccharides for drug discovery
GB0206505D0 (en) Pharmaceutical combination
GB2401043B (en) Drug
PL373409A1 (en) Pharmaceutical combination
GB0327742D0 (en) Novel uses of known drugs
IL176061A0 (en) Nitrooxyderivatives of antihypertensive drugs
PL355453A1 (en) Pharmaceutical agent